FI113044B - 2-hydrazinopyridinderivat - Google Patents

2-hydrazinopyridinderivat Download PDF

Info

Publication number
FI113044B
FI113044B FI952141A FI952141A FI113044B FI 113044 B FI113044 B FI 113044B FI 952141 A FI952141 A FI 952141A FI 952141 A FI952141 A FI 952141A FI 113044 B FI113044 B FI 113044B
Authority
FI
Finland
Prior art keywords
compound
formula
acid addition
addition salts
hours
Prior art date
Application number
FI952141A
Other languages
English (en)
Finnish (fi)
Other versions
FI952141A (sv
FI952141A0 (sv
Inventor
Michael Jeffrey Abrams
Gary James Bridger
David Aaron Schwartz
Sreenivasan Padmanabhan
Michael Evert Ultee
Original Assignee
Anormed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anormed Inc filed Critical Anormed Inc
Publication of FI952141A publication Critical patent/FI952141A/sv
Publication of FI952141A0 publication Critical patent/FI952141A0/sv
Application granted granted Critical
Publication of FI113044B publication Critical patent/FI113044B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (25)

1. Förening med den allmänna formeln I [ J—J—T—Q— Z ENNFT^N^ «> 5 där E är en alkylidengrupp eller H2, i vilket fall fö-reningen är i form av syraadditionssalt, 10. väljs bland -CO-NH-, -CO-Ο-, -CO-S- och -NH-CO-, T är en alkylenkedja eller, om J är -CO-NH-, är T resten av en aminosyradel, Q är disulfid, ester eller tioester och Z är bromacetat, maleimido, disulfid eller N-15 hydroxisuccinimidylester.
2. Förening enligt patentkrav 1, kännetecknad av att när E i formeln I är en alkyl idengrupp är den en förgrenad eller oförgrenad lägre alkylidenkedja med 1-4 kolatomer. • t 20
3. Förening enligt patentkrav 1 med formeln COOH J o 1 9 | h V—, f; J ·/: «’VV1 " 1 6 H • t < • 1 i • | och syraadditionssalter därav. t 25
4. Förening med den allmänna formeln Ia » » 1 • : · f J—CQ-NH—CttCQOH)-CiRh"-S“S-j·^ jj-R' (h) • ENNIT1 N ^ jvT » 113044 där E är säsom är definierat i patentkrav 1, R är H eller CH3 och R' är H eller N02.
5. Förening enligt patentkrav 4 med formeln X? i O /S Λ J H O N N 5 « eller syraadditionssalter därav.
6. Förening enligt patentkrav 4 med formeln SS'"01 XJ R I HjN,, XJ H O n jr
7. Förening enligt patentkrav 4 med formeln • · X) o v :··: nVr“ · H3Nn J H 0
8. Förening med formeln COOH h2n A J H o l }—> N ^ 10 H f n COOH 5 och syraadditionssalter därav.
9. Förening med formeln 0 0 0 °. rrAN^0A^Ao_^1 v'S'V h y-^ ) * 10 och syraadditionssalter därav.
10. Förening med formeln O o :: VW • · • · * » * *· ’* 15 och syraadditionssalter därav. f
< · ' 11. Förening med formeln * * * i
0 O ;v. ’ J H , 'N N ; h 1 t 20 eller syraadditionssalter därav. f * 1 * * » i t 113044
10 H där R är H eller CH3, eller syraadditionssalter därav.
12. Förening med formeln o o HjN, X J N N H 5 och syraadditionssalter därav.
13. Förening med formeln COOH H 10 och syraadditionssalter därav.
14. Förening med formeln : · 15 och syraadditionssalter därav. : : 15. Förening med formeln O 0 . N n H '' 20 och syraadditionssalter därav. 113044
15 H * 1 » · >;·· eller syraadditionssalter därav. < * > · * » i » · · 113044
16. Förening med formeln o o 9. 5 och syraadditionssalter därav.
17. Förening med formeln rA-vO ΗϊΝ'κΑ^ 0 N N H 10 och syraadditionssalter därav.
18. Förening med formeln o o ί H • · • j 15 och syraadditionssalter därav.
: 19. Förening med formeln * · · * » · O COOH :Y^8’· : H 2 0
20. Konjugat, kännetecknat av att det har bil- ! dats av en makromolekyls reaktion med en förening enligt i nägot av de föregäende patentkraven.
21. Konjugat enligt patentkrav 20, kännetecknat : av att makromolekylen omfattar immunoglobulin eller ett 25 fragment därav. 113044
22. Märkt makromolekyl, kännetecknad av att den innehäller en metallatom som är bunden tili ett konju-gat enligt patentkrav 20 eller 21.
23. Märkt makromolekyl enligt patentkrav 22, kän-5 netecknad av att metallen har valts frän radioisotoper- na Te och Re.
24. Förening med den allmänna formeln II M ® [ f-OONH-CCHjh-S— S ENNJT^iT 10 där E är sasom är definierat i patentkrav 1. » • · • · » t * » i · > · • I k · I ·
FI952141A 1992-11-05 1995-05-04 2-hydrazinopyridinderivat FI113044B (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB929223168A GB9223168D0 (en) 1992-11-05 1992-11-05 Improvements in molecule labelling
GB9223168 1992-11-05
GB9302259 1993-11-03
PCT/GB1993/002259 WO1994010149A1 (en) 1992-11-05 1993-11-03 Molecule labelling using 2-hydraninopyridine derivatives

Publications (3)

Publication Number Publication Date
FI952141A FI952141A (sv) 1995-05-04
FI952141A0 FI952141A0 (sv) 1995-05-04
FI113044B true FI113044B (sv) 2004-02-27

Family

ID=10724568

Family Applications (1)

Application Number Title Priority Date Filing Date
FI952141A FI113044B (sv) 1992-11-05 1995-05-04 2-hydrazinopyridinderivat

Country Status (19)

Country Link
US (1) US5679778A (sv)
EP (1) EP0667859B1 (sv)
JP (1) JP3542597B2 (sv)
KR (1) KR100295545B1 (sv)
AT (1) ATE195730T1 (sv)
AU (1) AU676863B2 (sv)
CA (1) CA2148595C (sv)
DE (1) DE69329293T2 (sv)
DK (1) DK0667859T3 (sv)
ES (1) ES2150950T3 (sv)
FI (1) FI113044B (sv)
GB (1) GB9223168D0 (sv)
GR (1) GR3034883T3 (sv)
HK (1) HK1013420A1 (sv)
HU (1) HU226459B1 (sv)
NO (1) NO305364B1 (sv)
NZ (1) NZ257376A (sv)
PT (1) PT667859E (sv)
WO (1) WO1994010149A1 (sv)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5942210A (en) * 1994-11-15 1999-08-24 Cytogen Corporation Methods for lyoprotecting a macromolecule using tricine
US5919934A (en) * 1997-02-19 1999-07-06 The George Washington University Compounds, compositions, and methods for cancer imaging and therapy
HUP0001261A3 (en) 1997-04-30 2001-11-28 Univ Washington Seattle Method of imaging cell death in vivo
US6403054B1 (en) * 1997-05-28 2002-06-11 Bristol-Myers Squibb Pharma Company Ternary ligand complexes useful as radiopharmaceuticals
US6844333B1 (en) * 1999-03-26 2005-01-18 The Trustees Of The University Of Pennsylvania Method of treating atherosclerosis
CA2723664A1 (en) * 2000-03-22 2001-09-27 Solulink, Incorporated Hydrazine-based and carbonyl-based bifunctional crosslinking reagents
US6686461B1 (en) 2000-03-22 2004-02-03 Solulink Bioscience, Inc. Triphosphate oligonucleotide modification reagents and uses thereof
US7102024B1 (en) 2000-08-01 2006-09-05 Schwartz David A Functional biopolymer modification reagents and uses thereof
WO2002080754A2 (en) 2001-04-03 2002-10-17 Theseus Imaging Corporation Methods for using annexin for detecting cell death in vivo and treating associated conditions
WO2002082044A2 (en) 2001-04-03 2002-10-17 The Board Of Trustees Of The Leland Stanford Junior University Method of imaging cell death in vivo
GB0130845D0 (en) * 2001-12-22 2002-02-06 James Peter Analysis
US7158353B2 (en) * 2003-11-06 2007-01-02 Seagate Technology Llc Magnetoresistive sensor having specular sidewall layers
JP5107716B2 (ja) * 2004-11-05 2012-12-26 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア 分子治療用生分解性リンカー
EP2942351B1 (en) * 2011-01-31 2016-10-12 ETH Zurich Trifunctional crosslinking reagents
CN103582496B (zh) 2011-06-03 2016-05-11 3M创新有限公司 具有聚乙二醇链段的异双官能连接基以及由其制成的免疫应答调节剂缀合物
BR112013031039B1 (pt) 2011-06-03 2020-04-28 3M Innovative Properties Co compostos de hidrazino 1h-imidazoquinolina-4-aminas, conjugados feitos destes compostos, composição e composição farmacêutica compreendendo ditos compostos e conjugados, usos dos mesmos e método de fabricação do conjugado

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861869A (en) * 1986-05-29 1989-08-29 Mallinckrodt, Inc. Coupling agents for joining radionuclide metal ions with biologically useful proteins
IL93432A (en) * 1989-02-24 1994-02-27 Johnson Mathey Inc Hydrazines and hydrazides, their conjugates with macromolecules, and such conjugates labeled with metallic ions
US5112953A (en) * 1989-12-29 1992-05-12 Neorx Corporation Radiolabeled proteins for diagnostic or therapeutic use

Also Published As

Publication number Publication date
DK0667859T3 (da) 2000-10-16
AU676863B2 (en) 1997-03-27
HK1013420A1 (en) 1999-08-27
ATE195730T1 (de) 2000-09-15
NO951751D0 (no) 1995-05-04
ES2150950T3 (es) 2000-12-16
CA2148595A1 (en) 1994-05-11
EP0667859A1 (en) 1995-08-23
GR3034883T3 (en) 2001-02-28
FI952141A (sv) 1995-05-04
AU5375594A (en) 1994-05-24
JP3542597B2 (ja) 2004-07-14
WO1994010149A1 (en) 1994-05-11
PT667859E (pt) 2001-02-28
US5679778A (en) 1997-10-21
DE69329293T2 (de) 2000-12-28
KR100295545B1 (ko) 2001-09-17
DE69329293D1 (de) 2000-09-28
CA2148595C (en) 2002-05-21
GB9223168D0 (en) 1992-12-16
HUT72332A (en) 1996-04-29
NO951751L (no) 1995-06-12
EP0667859B1 (en) 2000-08-23
JPH08502744A (ja) 1996-03-26
NZ257376A (en) 1996-02-27
NO305364B1 (no) 1999-05-18
FI952141A0 (sv) 1995-05-04
KR950704256A (ko) 1995-11-17
HU226459B1 (en) 2008-12-29

Similar Documents

Publication Publication Date Title
FI113044B (sv) 2-hydrazinopyridinderivat
US5206370A (en) Certain pyridyl hydrazines and hydrazides useful for protein labeling
JP2683080B2 (ja) トリ‐アザ大環状化合物及びそれらの金属錯体
EP0188256A2 (en) Metal radionuclide labeled proteins for diagnosis and therapy
AU2253388A (en) Tetra-aza macrocycles and metal complexes thereof
US5218128A (en) Bifunctional coupling agents and radionuclide labeled compositions prepared therefrom
JP5705434B2 (ja) キレート剤
JP3073997B2 (ja) タンパク質の標識化
JPH08504400A (ja) 放射性薬剤として使用する金属オキシムキレート
Makris et al. Synthesis, characterization, and biological evaluation of new biotinylated 99mTc/Re‐tricarbonyl complexes
Adelstein Harvard-MIT research program in short-lived radiopharmaceuticals. Technical progress report, 1991
NO179585B (no) Fremgangsmåte ved fremstilling av antistoffkonjugater med makrocykliske bifunksjonelle chelaterte komplekser

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: ANORMED INC.

MA Patent expired